Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Incyte Reaches Agreement With FDA On SPA For JAK1/JAK2 Inhibitor
Incyte has reached an agreement with the FDA regarding a Special Protocol Assessment. This SPA is on the design of a pivotal phase III trial for JAK1/JAK2 Inhibitor
Incyte has reached an agreement with the FDA regarding a Special Protocol Assessment. This SPA is on the design of a pivotal phase III trial for JAK1/JAK2 Inhibitor
Medicago and Genopole have signed a partnership agreement with a plan to build a commercial facility to manufacture pandemic and seasonal influenza vaccines in France. Both the firms
Quest Diagnostic has posted an increase in the net revenues to $1.9 billion for the second quarter of 2009, as compared to $1.8 billion for the same period
GlaxoSmithKline (GSK) and Enigma Diagnostics have signed worldwide agreements to develop and supply the first point of care diagnostic influenza tests. It is to identify specific influenza virus
R-Tech Ueno has completed phase 1 clinical study of RK-023, a therapeutic drug of androgenetic alopecia. The phase 1 clinical study of RK-023 was a patch test, single
Pfizer has declared the results for a 96-week follow up data from the MERITES analysis, for HIV patients taking Celsentri/Selzentry (maraviroc) in combination with Combivir (zidovudine/lamivudine). The results
For the 2009 second quarter, Schering-Plough has reported GAAP net income of $633m or 38 cents per common share, compared to $424m or 26 cents per common share
Pfizer has posted a Q2 revenues of $11.0 billion, which is a decrease of 9% compared with the year-ago quarter. For second-quarter 2009, US revenues were $4.5 billion,
OSI and AVEO have expanded the drug discovery and translational research collaboration announced in October 2007. The alliance is anchored around developing molecular targeted therapies to target the
Ranbaxy has received final approval in Canada to manufacture and market Ran-Simvastatin 5mg, 10mg, 20mg, 40mg and 80mg tablets (Simvastatin), from Health Canada, Therapeutic Products Directorate (TPD). Ran-Simvastatin